A cost-effectiveness analysis of universal hepatitis C screening in all United States pregnancies

Abstract

Objective

To evaluate the cost-effectiveness of universal screening for HCV among all pregnant women in the United States.

Methods

We designed a decision-analytic model to evaluate the cost-effectiveness and outcomes associated with universal HCV screening in pregnancy compared to no screening. A theoretical cohort of 3.9 million women, the approximate number of annual live births in the United States was used. Outcomes included hepatocellular carcinoma, decompensated cirrhosis, liver transplant and death, in addition to cost and quality-adjusted life years (QALYs). Model inputs were derived from the literature and the willingness-to-pay threshold was $100,000 per QALY. Sensitivity analysis were conducted to evaluate the robustness of the results.

Results

In a theoretical cohort of 3.9 million women, universal HCV screening resulted in 3003 fewer cases of hepatocellular carcinoma, 1484 fewer decompensated cirrhosis, 46 fewer liver transplants and 2665 fewer deaths from HCV when compared to no screening. Universal HCV screening was found to be the dominant strategy, meaning it resulted in lower costs and higher QALYs. Sensitivity analyses showed our model was robust over a wide range of assumptions.

Conclusion

Among pregnant women in the United States, universal HCV screening is cost effective compared with no screening.

Keywords:

• Hepatitis C
• obstetrics
• pregnancy
• cost-effectiveness analysis
• screening
• economics

Disclosure statement

No potential conflict of interest was reported by the author(s).